130 related articles for article (PubMed ID: 22285028)
1. Synthesis and evaluation of debromohymenialdisine-derived Chk2 inhibitors.
Saleem RS; Lansdell TA; Tepe JJ
Bioorg Med Chem; 2012 Feb; 20(4):1475-81. PubMed ID: 22285028
[TBL] [Abstract][Full Text] [Related]
2. Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine.
Sharma V; Tepe JJ
Bioorg Med Chem Lett; 2004 Aug; 14(16):4319-21. PubMed ID: 15261294
[TBL] [Abstract][Full Text] [Related]
3. Radioprotection by hymenialdisine-derived checkpoint kinase 2 inhibitors.
Nguyen TN; Saleem RS; Luderer MJ; Hovde S; Henry RW; Tepe JJ
ACS Chem Biol; 2012 Jan; 7(1):172-84. PubMed ID: 22004065
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine.
Curman D; Cinel B; Williams DE; Rundle N; Block WD; Goodarzi AA; Hutchins JR; Clarke PR; Zhou BB; Lees-Miller SP; Andersen RJ; Roberge M
J Biol Chem; 2001 May; 276(21):17914-9. PubMed ID: 11279124
[TBL] [Abstract][Full Text] [Related]
5. A new glycociamidine ring precursor: syntheses of (Z)-hymenialdisine, (Z)-2-debromohymenialdisine, and (+/-)-endo-2-debromohymenialdisine.
Papeo G; Posteri H; Borghi D; Varasi M
Org Lett; 2005 Dec; 7(25):5641-4. PubMed ID: 16321011
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor.
Lountos GT; Tropea JE; Zhang D; Jobson AG; Pommier Y; Shoemaker RH; Waugh DS
Protein Sci; 2009 Jan; 18(1):92-100. PubMed ID: 19177354
[TBL] [Abstract][Full Text] [Related]
7. Preparation of hymenialdisine, analogues and their evaluation as kinase inhibitors.
Nguyen TN; Tepe JJ
Curr Med Chem; 2009; 16(24):3122-43. PubMed ID: 19689287
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint kinase inhibitors: a review of the patent literature.
Janetka JW; Ashwell S
Expert Opin Ther Pat; 2009 Feb; 19(2):165-97. PubMed ID: 19441917
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and CHK1 inhibitory potency of Hymenialdisine analogues.
Parmentier JG; Portevin B; Golsteyn RM; Pierré A; Hickman J; Gloanec P; De Nanteuil G
Bioorg Med Chem Lett; 2009 Feb; 19(3):841-4. PubMed ID: 19111462
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1.
Wei L; Gao X; Warne R; Hao X; Bussiere D; Gu XJ; Uno T; Liu Y
Bioorg Med Chem Lett; 2010 Jul; 20(13):3897-902. PubMed ID: 20627557
[TBL] [Abstract][Full Text] [Related]
11. Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange.
Oliver AW; Paul A; Boxall KJ; Barrie SE; Aherne GW; Garrett MD; Mittnacht S; Pearl LH
EMBO J; 2006 Jul; 25(13):3179-90. PubMed ID: 16794575
[TBL] [Abstract][Full Text] [Related]
12. Pyrrolocarbazoles as checkpoint 1 kinase inhibitors.
Hénon H; Conchon E; Hugon B; Messaoudi S; Golsteyn RM; Prudhomme M
Anticancer Agents Med Chem; 2008 Aug; 8(6):577-97. PubMed ID: 18690823
[TBL] [Abstract][Full Text] [Related]
13. Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy.
Lountos GT; Jobson AG; Tropea JE; Self CR; Zhang G; Pommier Y; Shoemaker RH; Waugh DS
J Struct Biol; 2011 Dec; 176(3):292-301. PubMed ID: 21963792
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.
Hilton S; Naud S; Caldwell JJ; Boxall K; Burns S; Anderson VE; Antoni L; Allen CE; Pearl LH; Oliver AW; Wynne Aherne G; Garrett MD; Collins I
Bioorg Med Chem; 2010 Jan; 18(2):707-18. PubMed ID: 20022510
[TBL] [Abstract][Full Text] [Related]
15. Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.
Smith L; Piatnitski EL; Kiselyov AS; Ouyang X; Chen X; Burdzovic-Wizemann S; Xu Y; Pan W; Chen X; Wang Y; Rosler RL; Patel SN; Chiang HH; Milligan DL; Columbus J; Wong WC; Doody JF; Hadari YR
Bioorg Med Chem Lett; 2006 Mar; 16(6):1643-6. PubMed ID: 16412636
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cytokine production by hymenialdisine derivatives.
Sharma V; Lansdell TA; Jin G; Tepe JJ
J Med Chem; 2004 Jul; 47(14):3700-3. PubMed ID: 15214798
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and target identification of hymenialdisine analogs.
Wan Y; Hur W; Cho CY; Liu Y; Adrian FJ; Lozach O; Bach S; Mayer T; Fabbro D; Meijer L; Gray NS
Chem Biol; 2004 Feb; 11(2):247-59. PubMed ID: 15123286
[TBL] [Abstract][Full Text] [Related]
18. Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1).
Tasdemir D; Mallon R; Greenstein M; Feldberg LR; Kim SC; Collins K; Wojciechowicz D; Mangalindan GC; Concepción GP; Harper MK; Ireland CM
J Med Chem; 2002 Jan; 45(2):529-32. PubMed ID: 11784156
[TBL] [Abstract][Full Text] [Related]
19. Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors.
Rao AU; Xiao D; Huang X; Zhou W; Fossetta J; Lundell D; Tian F; Trivedi P; Aslanian R; Palani A
Bioorg Med Chem Lett; 2012 Jan; 22(2):1068-72. PubMed ID: 22182499
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors.
Wang L; Sullivan GM; Hexamer LA; Hasvold LA; Thalji R; Przytulinska M; Tao ZF; Li G; Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Merta P; Kovar P; Bouska JJ; Zhang H; Park C; Stewart KD; Sham HL; Sowin TJ; Rosenberg SH; Lin NH
J Med Chem; 2007 Aug; 50(17):4162-76. PubMed ID: 17658776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
